There were no significant differences in changes in PROMIS anxiety, PROMIS depression, or HIP-10 scores of participants based on time from completion of active treatment to the time of the workshop (≤6 months vs >6 months), stage (stage 0 or 1 vs stage 2 or 3), hormone receptor status (positive vs negative) or nodal status at any follow-up point. This evidence concerns the gene NR4A1 and depressive disorder.